The startup develops small molecule antiandrogen drugs that target prostate cancer and neurodegenerative diseases while also providing non-toxic treatments for hair loss and acne. By utilizing androgen receptor antagonists, the company aims to improve the quality of life for millions affected by these conditions without disrupting hormonal functions in other areas of the body.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Androgenetic alopecia (AGA) and acne are common conditions often treated with therapies that cause systemic antiandrogenic side effects due to their impact on hormone levels throughout the body. Current treatments may not be suitable for all patients, and there is a need for more targeted therapies that minimize systemic effects.
Solution
Aranda Pharma is developing ADA-308, a novel, highly potent, locally acting antiandrogen drug candidate for androgenetic alopecia and acne. ADA-308 is designed to address the root cause of these conditions by targeting androgen receptors in the skin without disrupting hormonal functions systemically. Preclinical studies have demonstrated excellent efficacy compared to existing treatments and other pipeline products, while also exhibiting a clean safety profile. The topical application of ADA-308 allows for targeted treatment, reducing the risk of systemic side effects commonly associated with traditional antiandrogen therapies.
Target Audience
The primary target audience includes individuals suffering from androgenetic alopecia (pattern hair loss) and acne, as well as dermatologists and other healthcare professionals seeking more effective and safer treatment options.
Features
- Highly potent, locally acting antiandrogen
- Topical application for targeted treatment
- Designed to minimize systemic antiandrogenic side effects
- Demonstrated excellent efficacy in preclinical studies for AGA and acne
- Addresses androgen-induced excess sebum production in acne